DT-Web

DB00488 - Altretamine


Identification
Name Altretamine
Accession Number DB00488 (APRD00652)
Type small molecule
Description An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. [PubChem]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 210.2794
Groups approved
Monoisotopic Weight 210.159294606
Pharmacology
Indication For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
Mechanism of action The precise mechanism by which altretamine exerts its cytotoxic effect is unknown although it is classified as an alkylating anti-neoplastic agent. Through this mechanism, the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.
Absorption Not Available
Protein binding 94%
Biotransformation Not Available
Route of elimination Human urinary metabolites were Ndemethylated homologues of altretamine with <1% unmetabolized altretamine excreted at 24 hours.
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Amitriptyline Risk of severe hypotension
Amoxapine Risk of severe hypotension
Clomipramine Risk of severe hypotension
Desipramine Risk of severe hypotension
Doxepin Risk of severe hypotension
Imipramine Risk of severe hypotension
Isocarboxazid Risk of severe hypotension
Nortriptyline Risk of hypotension
Phenelzine Risk of severe hypotension
Rasagiline Risk of severe hypotension
Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Food Interactions Not Available

Targets


DNA
Name DNA
Gene Name Not Available
Pharmacological action yes
Actions other/unknown
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Damia G, D'Incalci M: Clinical pharmacokinetics of altretamine. Clin Pharmacokinet. 1995 Jun;28(6):439-48. - Pubmed
DTHybrid score Not Available

Predictions


Id Partner name Gene Name Score
↑